Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment
暂无分享,去创建一个
Christos Davatzikos | Susan M. Resnick | Michael A. Kraut | Yang An | Madhav Thambisetty | Anna Kinsey | Deepthi Koka | Muzamil Saleem | Andreas Gupsilonntert | Luigi Ferrucci | Simon Lovestone | L. Ferrucci | S. Resnick | C. Davatzikos | M. Kraut | Y. An | S. Lovestone | M. Thambisetty | Muzamil Saleem | D. Koka | Anna M. Kinsey | Andreas Gupsilonntert
[1] K. Blennow,et al. Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. , 2001, Journal of Alzheimer's disease : JAD.
[2] Lars-Olof Wahlund,et al. Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer’s Disease Patients and Healthy Individuals , 2008, Neurochemical Research.
[3] Yoshitaka Nagai,et al. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. , 2009, Journal of biochemistry.
[4] Constantine G Lyketsos,et al. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies , 2008, International Psychogeriatrics.
[5] Albert Hofman,et al. Plasma clusterin and the risk of Alzheimer disease. , 2011, JAMA.
[6] J A Yesavage,et al. 'How far' vs 'how fast' in Alzheimer's disease. The question revisited. , 1994, Archives of neurology.
[7] S. Resnick,et al. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI , 2009, Neurology.
[8] M. Folstein,et al. The Mini-Mental State Examination. , 1983, Archives of general psychiatry.
[9] H. Hartley,et al. Maximum-likelihood estimation for the mixed analysis of variance model. , 1967, Biometrika.
[10] Christopher M. Dobson,et al. Clusterin facilitates in vivo clearance of extracellular misfolded proteins , 2011, Cellular and Molecular Life Sciences.
[11] S. Resnick,et al. An image-processing system for qualitative and quantitative volumetric analysis of brain images. , 1998, Journal of computer assisted tomography.
[12] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[13] L. Kiemeney,et al. Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.
[14] C. Jack,et al. Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis , 2011, Neurobiology of Aging.
[15] T. Suuronen,et al. Clusterin: A forgotten player in Alzheimer's disease , 2009, Brain Research Reviews.
[16] N. Jahanshad,et al. Common Alzheimer's Disease Risk Variant Within the CLU Gene Affects White Matter Microstructure in Young Adults , 2011, The Journal of Neuroscience.
[17] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[18] L. French,et al. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. , 1994, The Journal of clinical investigation.
[19] Nick C Fox,et al. Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .
[20] A Rostagno,et al. Apolipoprotein J (clusterin) and Alzheimer's disease , 2000, Microscopy research and technique.
[21] H. Braak,et al. Evolution of Alzheimer's disease related cortical lesions. , 1998, Journal of neural transmission. Supplementum.
[22] P. Sachdev,et al. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease , 2009, Brain Research Reviews.
[23] L. French,et al. Clusterin: modulation of complement function , 1994, Clinical and experimental immunology.
[24] Bruce J Aronow,et al. ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.
[25] Christopher Clark,et al. Disease-modifying therapies for Alzheimer disease , 2007, Neurology.
[26] Guy B. Williams,et al. Comparative Reliability of Total Intracranial Volume Estimation Methods and the Influence of Atrophy in a Longitudinal Semantic Dementia Cohort , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[27] P. Bosco,et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.
[28] P. Giannakopoulos,et al. Possible neuroprotective role of clusterin in Alzheimer’s disease: a quantitative immunocytochemical study , 1998, Acta Neuropathologica.
[29] Carol Brayne,et al. Age, neuropathology, and dementia. , 2009, The New England journal of medicine.
[30] A. Burns. Clinical diagnosis of Alzheimer's disease , 1991 .
[31] Stephen J. Finch,et al. Genome-wide association study of genetic loci and Alzheimer disease. , 2010 .
[32] Nick C Fox,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.
[33] Dinggang Shen,et al. HAMMER: hierarchical attribute matching mechanism for elastic registration , 2002, IEEE Transactions on Medical Imaging.
[34] Bruce J Aronow,et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[36] Sudha Seshadri,et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.
[37] R. Petersen. Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.